Department of Psychiatry, University of Cambridge and the Cambridge and Peterborough Foundation Trust, Douglas House, 18b Trumpington Road Cambridge, UK.
Trials. 2011 Jul 13;12:175. doi: 10.1186/1745-6215-12-175.
Up to 70% of adolescents with moderate to severe unipolar major depression respond to psychological treatment plus Fluoxetine (20-50 mg) with symptom reduction and improved social function reported by 24 weeks after beginning treatment. Around 20% of non responders appear treatment resistant and 30% of responders relapse within 2 years. The specific efficacy of different psychological therapies and the moderators and mediators that influence risk for relapse are unclear. The cost-effectiveness and safety of psychological treatments remain poorly evaluated.
METHODS/DESIGN: Improving Mood with Psychoanalytic and Cognitive Therapies, the IMPACT Study, will determine whether Cognitive Behavioural Therapy or Short Term Psychoanalytic Therapy is superior in reducing relapse compared with Specialist Clinical Care. The study is a multicentre pragmatic effectiveness superiority randomised clinical trial: Cognitive Behavioural Therapy consists of 20 sessions over 30 weeks, Short Term Psychoanalytic Psychotherapy 30 sessions over 30 weeks and Specialist Clinical Care 12 sessions over 20 weeks. We will recruit 540 patients with 180 randomised to each arm. Patients will be reassessed at 6, 12, 36, 52 and 86 weeks. Methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of assessments with control for rater shift, research assessors independent of treatment team and blind to randomization, analysis by intention to treat, data management using remote data entry, measures of quality assurance, advanced statistical analysis, manualised treatment protocols, checks of adherence and competence of therapists and assessment of cost-effectiveness. We will also determine whether time to recovery and/or relapse are moderated by variations in brain structure and function and selected genetic and hormone biomarkers taken at entry.
The objective of this clinical trial is to determine whether there are specific effects of specialist psychotherapy that reduce relapse in unipolar major depression in adolescents and thereby costs of treatment to society. We also anticipate being able to utilise psychotherapy experience, neuroimaging, genetic and hormone measures to reveal what techniques and their protocols may work best for which patients.
Current Controlled Trials ISRCTN83033550.
多达 70%的中重度单相重性抑郁青少年在接受心理治疗联合氟西汀(20-50mg)治疗后,症状得到缓解,社会功能得到改善,这种改善在治疗开始后 24 周即可观察到。约 20%的无反应者表现出治疗抵抗,30%的反应者在 2 年内复发。不同心理治疗的具体疗效以及影响复发风险的调节和中介因素尚不清楚。心理治疗的成本效益和安全性仍未得到充分评估。
方法/设计:改善情绪的精神分析和认知治疗,即 IMPACT 研究,将确定认知行为疗法或短期精神分析疗法是否优于专科临床护理,从而降低复发风险。该研究是一项多中心实用有效性优效性随机临床试验:认知行为疗法包含 30 周的 20 次治疗,短期精神分析心理疗法包含 30 周的 30 次治疗,专科临床护理包含 20 周的 12 次治疗。我们将招募 540 名患者,其中 180 名随机分为每组。患者将在 6、12、36、52 和 86 周时进行重新评估。研究的方法学方面包括系统招募、明确的纳入标准、评估的可靠性检查,包括评估者偏移的控制、治疗团队之外的研究评估者和随机化的盲法、意向治疗分析、远程数据录入的数据管理、质量保证措施、高级统计分析、治疗方案的标准化、治疗师的依从性和能力检查以及成本效益评估。我们还将确定恢复和/或复发的时间是否受到大脑结构和功能以及在进入时选择的遗传和激素生物标志物的变化的调节。
本临床试验的目的是确定专科心理治疗是否具有降低青少年单相重性抑郁复发的特定效果,从而降低社会的治疗成本。我们还期望能够利用心理治疗经验、神经影像学、遗传和激素测量结果,揭示哪些技术及其方案可能对哪些患者最有效。
当前对照试验 ISRCTN83033550。